EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma

Christine Nitschke iD, Benedikt Markmann, Philipp Walter, Anita Badbaran, Marie Tölle, Jolanthe Kropidlowski, Yassine Belloum, Mara R Goetz, Jan Bardenhagen, Louisa Stern, Joseph Tintelnot iD, Martin Schönlein iD und 8 weitere

Clinical Chemistry · 01.03.2023 · 69 (3) · 295-307

DOI: 10.1093/clinchem/hvac214 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 16.01.2023. Verfasst von Christine Nitschke und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg 20246, Germany. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

KRAS circulating tumor DNA (ctDNA) has shown biomarker potential for pancreatic ductal adenocarcinoma (PDAC) but has not been applied in clinical routine yet. We aim to improve clinical applicability of ctDNA detection in PDAC and to study the impact of blood-draw site and time point on the detectability and prognostic role of KRAS mutations.

Methods

221 blood samples from 108 PDAC patients (65 curative, 43 palliative) were analyzed. Baseline peripheral and tumor-draining portal venous (PV), postoperative, and follow-up blood were analyzed and correlated with prognosis.

Results

Significantly higher KRAS mutant detection rates and copy numbers were observed in palliative compared to curative patients baseline blood (58.1% vs 24.6%; P = 0.002; and P < 0.001). Significantly higher KRAS mutant copies were found in PV blood compared to baseline (P < 0.05) samples. KRAS detection in pre- and postoperative and PV blood were significantly associated with shorter recurrence-free survival (all P < 0.015) and identified as independent prognostic markers. KRAS ctDNA status was also an independent unfavorable prognostic factor for shorter overall survival in both palliative and curative cohorts (hazard ratio [HR] 4.9, P = 0.011; HR 6.9, P = 0.008).

Conclusions

KRAS ctDNA detection is an independent adverse prognostic marker in curative and palliative PDAC patients—at all sites of blood draw and a strong follow-up marker. The most substantial prognostic impact was seen for PV blood, which could be an effective novel tool for identifying prognostic borderline patients—guiding future decision-making on neoadjuvant treatment despite anatomical resectability. In addition, higher PV mutant copy numbers contribute to an improved technical feasibility.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansPrognosisProto-Oncogene Proteins p21(ras)Neoplasm Recurrence, LocalMutationBiomarkers, Tumor

Substanzen

Proto-Oncogene Proteins p21(ras)Biomarkers, TumorKRAS protein, human

Autor:innen und Institutionen

  • Department of General, Visceral and Thoracic Surgery, University Hospital Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Mildred Scheel Cancer Career Center, Hamburg 20246, Germany.
  • Institute of Tumor Biology, University Hospital Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Clinic for Stem Cell Transplantation, University Hospital Hamburg-Eppendorf, Hamburg 20246, Germany.
  • II. Medical Clinic and Polyclinic (Oncology), University Hospital Hamburg-Eppendorf, Hamburg 20246, Germany.
  • Department of Pathology, University Medical Center, University of Groningen, Groningen 9700 RB, Netherlands.

ORCID-Profile: Christine Nitschke, Joseph Tintelnot, Martin Schönlein, Ronald Simon, Harriet Wikman

Zitieren

APA

Nitschke, C., Markmann, B., Walter, P., Badbaran, A., Tölle, M., Kropidlowski, J., Belloum, Y., Goetz, M. R., Bardenhagen, J., Stern, L., Tintelnot, J., Schönlein, M., Sinn, M., van der Leest, P., Simon, R., Heumann, A., Izbicki, J. R., Pantel, K., Wikman, H., & Uzunoglu, F. G. (2023). Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Clinical Chemistry, 69(3), 295-307. https://doi.org/10.1093/clinchem/hvac214

Vancouver

Nitschke C, Markmann B, Walter P, Badbaran A, Tölle M, Kropidlowski J, et al. Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma. Clinical Chemistry. 2023;69(3):295-307. doi:10.1093/clinchem/hvac214

BibTeX
@article{Nitschke2023,
  author = {Nitschke, Christine and Markmann, Benedikt and Walter, Philipp and Badbaran, Anita and Tölle, Marie and Kropidlowski, Jolanthe and Belloum, Yassine and Goetz, Mara R and Bardenhagen, Jan and Stern, Louisa and Tintelnot, Joseph and Schönlein, Martin and Sinn, Marianne and van der Leest, Paul and Simon, Ronald and Heumann, Asmus and Izbicki, Jakob R and Pantel, Klaus and Wikman, Harriet and Uzunoglu, Faik G},
  title = {Peripheral and Portal Venous KRAS ctDNA Detection as Independent Prognostic Markers of Early Tumor Recurrence in Pancreatic Ductal Adenocarcinoma},
  journal = {Clinical Chemistry},
  year = {2023},
  volume = {69},
  number = {3},
  pages = {295--307},
  doi = {10.1093/clinchem/hvac214}
}
Kostenlos starten →